STOCK TITAN

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong financial results for Q2 2024, with revenue increasing 48% to $29.9 million. The company's gross margin improved by 50 basis points to 62.1%. Despite a net loss of $3.9 million, Xtant achieved positive Adjusted EBITDA of $0.5 million.

Key highlights include the launch of two new amniotic membrane allograft products, signing 15 new distributors, and securing 20 IDN contracts. The company also entered a $5.0 million private placement to strengthen its balance sheet.

Xtant reaffirmed its 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth. The company expects continued momentum with new product launches, increased distributor penetration, and improved margins in the second half of 2024.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) ha riportato risultati finanziari solidi per il secondo trimestre del 2024, con un aumento del fatturato del 48% a $29.9 milioni. Il margine lordo dell'azienda è migliorato di 50 punti base, raggiungendo il 62.1%. Nonostante una perdita netta di $3.9 milioni, Xtant ha ottenuto un EBITDA rettificato positivo di $0.5 milioni.

Tra i principali punti salienti ci sono il lancio di due nuovi prodotti di allograft di membrana amniotica, la firma di 15 nuovi distributori e l'ottenimento di 20 contratti IDN. L'azienda ha inoltre avviato un collocamento privato di $5.0 milioni per rafforzare il proprio bilancio.

Xtant ha confermato le previsioni di fatturato per il 2024 tra $116-$120 milioni, prevedendo una crescita annuale del 27-31%. L'azienda si aspetta di continuare a beneficiare dell’inerzia generata dai lanci di nuovi prodotti, dall’aumento della penetrazione dei distributori e dal miglioramento dei margini nella seconda metà del 2024.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) reportó resultados financieros sólidos para el segundo trimestre de 2024, con un aumento del 48% en los ingresos hasta $29.9 millones. El margen bruto de la empresa mejoró 50 puntos básicos, alcanzando el 62.1%. A pesar de una pérdida neta de $3.9 millones, Xtant logró un EBITDA ajustado positivo de $0.5 millones.

Los puntos clave incluyen el lanzamiento de dos nuevos productos de aloinjerto de membrana amniótica, la firma de 15 nuevos distribuidores y la obtención de 20 contratos IDN. La compañía también realizó una colocación privada de $5.0 millones para fortalecer su balance.

Xtant reafirmó su guía de ingresos para 2024 de $116-$120 millones, proyectando un crecimiento anual del 27-31%. La empresa espera mantener el impulso con el lanzamiento de nuevos productos, mayor penetración de distribuidores y márgenes mejorados en la segunda mitad de 2024.

Xtant Medical Holdings, Inc. (NYSE American: XTNT)는 2024년 2분기 강력한 재무 실적을 보고하며, 수익이 48% 증가한 $29.9 백만에 달했습니다. 회사의 매출 총 이익률은 50bp 개선되어 62.1%에 도달했습니다. $3.9 백만의 순손실에도 불구하고, Xtant는 긍정적인 조정 EBITDA $0.5 백만을 달성했습니다.

주요 하이라이트에는 두 개의 새로운 양막 이식 편제품 출시, 15개의 새로운 유통업체 계약 체결, 20개의 IDN 계약 확보가 포함됩니다. 또한 이 회사는 자산 강화를 위해 $5.0 백만의 사모 배정을 실시했습니다.

Xtant는 2024년 매출 전망을 $116-$120 백만으로 재확인하며, 연간 27-31%의 성장을 예상하고 있습니다. 회사는 2024년 하반기에 새로운 제품 출시, 유통업체 침투 증가 및 개선된 마진을 통해 지속적인 모멘텀을 기대하고 있습니다.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) a annoncé de solides résultats financiers pour le deuxième trimestre 2024, avec un chiffre d'affaires en hausse de 48% à $29,9 millions. La marge brute de l'entreprise a augmenté de 50 points de base, atteignant 62,1%. Malgré une perte nette de $3,9 millions, Xtant a réalisé un EBITDA ajusté positif de $0,5 million.

Les points clés incluent le lancement de deux nouveaux produits d'allogreffe de membrane amniotique, la signature de 15 nouveaux distributeurs et la sécurisation de 20 contrats IDN. L'entreprise a également procédé à un placement privé de $5,0 millions pour renforcer son bilan.

Xtant a réaffirmé ses prévisions de chiffre d'affaires pour 2024 de $116-$120 millions, projetant une croissance annuelle de 27-31%. L'entreprise s'attend à une dynamique continue avec de nouveaux lancements de produits, une plus grande pénétration des distributeurs et une amélioration des marges dans la seconde moitié de 2024.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) hat für das zweite Quartal 2024 solide finanzielle Ergebnisse berichtet, mit einem Umsatzanstieg von 48% auf $29,9 Millionen. Die Bruttomarge des Unternehmens verbesserte sich um 50 Basispunkte auf 62,1%. Trotz eines Nettoverlusts von $3,9 Millionen erzielte Xtant ein positives bereinigtes EBITDA von $0,5 Millionen.

Wesentliche Höhepunkte sind die Einführung von zwei neuen amniotischen Membran-Transplantatprodukten, der Abschluss von 15 neuen Vertriebspartnern und die Sicherung von 20 IDN-Verträgen. Darüber hinaus hat das Unternehmen eine Privatplatzierung von $5,0 Millionen durchgeführt, um die Bilanz zu stärken.

Xtant bestätigte seine Umsatzprognose für 2024 von $116-$120 Millionen und prognostiziert ein jährliches Wachstum von 27-31%. Das Unternehmen erwartet, dass die Dynamik mit neuen Produkteinführungen, einer erhöhten Verbreitung von Vertriebspartnern und verbesserten Margen in der zweiten Jahreshälfte 2024 anhält.

Positive
  • Revenue increased 48% year-over-year to $29.9 million
  • Gross margin improved by 50 basis points to 62.1%
  • Achieved positive Adjusted EBITDA of $0.5 million
  • Launched two new amniotic membrane allograft products
  • Signed 15 new distributors and secured 20 IDN contracts
  • Entered into a $5.0 million private placement to strengthen balance sheet
  • Reaffirmed 2024 revenue guidance of $116-$120 million, projecting 27-31% annual growth
Negative
  • Net loss increased to $3.9 million compared to $2.2 million in the year-ago quarter
  • Operating expenses increased to $21.5 million from $13.9 million in Q2 2023
  • Cash and cash equivalents decreased to $5.4 million from $5.7 million at the end of 2023
  • Lingering supply chain challenges reported

Xtant Medical's Q2 2024 results show strong revenue growth of 48% year-over-year, reaching $29.9 million. This growth is primarily attributed to the acquisition of Surgalign Holdings' hardware and biologics business. The company's gross margin improved by 50 basis points to 62.1%, indicating better production efficiency.

However, the net loss widened to $3.9 million from $2.2 million in the previous year, mainly due to increased operating expenses. Positively, Adjusted EBITDA improved to $0.5 million from $0.1 million, marking the fifth consecutive quarter of positive Adjusted EBITDA.

The company's cash position remains tight at $5.4 million, but the announced $5 million private placement should provide some financial flexibility. Xtant's reaffirmed 2024 revenue guidance of $116-120 million suggests continued strong growth expectations.

Xtant's Q2 performance demonstrates solid market traction in the spinal disorder treatment sector. The launch of new amniotic membrane allograft products (SimpliGraft™ and SimpliMax™) and record sales for Cortera™ indicate successful product diversification and market acceptance.

The addition of 15 new distributors and 20 IDN contracts in Q2 suggests an expanding market reach and potential for sustained growth. However, the mention of lingering supply chain challenges is a concern, though the company is addressing this through self-produced products.

The focus on internally produced products could lead to improved margins and greater control over the supply chain, which is important in the medical device industry. The company's strategy of combining organic growth with strategic acquisitions appears to be yielding positive results, positioning Xtant well in the competitive spinal treatment market.

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

  • Revenue of $29.9 million, up 48%, compared to the prior year quarter

  • Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter

  • Net loss of $3.9 million compared to $2.2 million in the year ago quarter

  • Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter

Recent Business Highlights

  • Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter

  • Signed 15 new distributors in the second quarter

  • Awarded 20 IDN contracts in the second quarter

  • Entered into a $5.0 million private placement on August 7, 2024

Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024. We delivered strong revenue growth, despite lingering supply chain challenges, which we are addressing through the launch of new, self-produced products. Furthermore, the second quarter marks our fifth consecutive quarter of positive Adjusted EBITDA, and our recent acquisitions are performing at or ahead of our expectations."

Browne continued, "We enter the second half of the year with significant business momentum and, after our recently announced private placement, a stronger balance sheet to support our strategic growth plans. In the second half of 2024, we expect additional new product launches, increased penetration within our distributor network, and an increase in the number of internally produced products, which will coalesce to drive further margin improvement on higher sales and generate positive operating cash flow. We are energized by the prospects for our business and remain committed to our mission of honoring the gift of donation by allowing our patients to live as full and complete a life as possible."

Second Quarter 2024 Financial Results

Total revenue for the three months ended June 30, 2024 was $29.9 million, an increase of 48% compared to $20.2 million in the prior year quarter. The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings' hardware and biologics business.

Gross margin for the second quarter of 2024 was 62.1%, compared to 61.6% for the prior year quarter, an increase of 50 basis points. The increase is primarily due to greater scale and improved production efficiency, which was partially offset by increased charges for excess and obsolete inventory and non-absorbed costs and sales mix.

Operating expenses for the second quarter of 2024 totaled $21.5 million, compared to $13.9 million for the second quarter of 2023. The increase was primarily due to additional commission expense resulting from revenue growth, additional compensation expense related to additional headcount and additional stock-based compensation.

Net loss for the second quarter of 2024 was $3.9 million, or $(0.03) per share, compared to a net loss of $2.2 million, or $(0.02) per share in the year ago quarter.

Non-GAAP Adjusted EBITDA for the second quarter of 2024 was $0.5 million, compared to non-GAAP Adjusted EBITDA of $0.1 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, acquisition-related expenses, acquisition-related fair value adjustments and foreign currency exchange gains. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

As of June 30, 2024, the Company had $5.4 million of cash and cash equivalents compared to $5.7 million as of December 31, 2023. In a separate release issued today, the Company announced it has entered into a securities purchase agreement with an existing institutional investor to sell $5.0 million shares of its common stock in a private placement at a purchase price of $0.64 per share.

2024 Financial Guidance

Xtant Medical reaffirms its expectation for full year 2024 revenue to $116 million to $120 million, which represents annual revenue growth of approximately 27% to 31% compared to full year 2023 revenue.

Conference Call

Xtant Medical will host a webcast and conference call to discuss second quarter 2024 financial results at 9:00 am ET on Friday, August 9, 2024.

To access the webcast, visit https://www.webcaster4.com/Webcast/Page/3039/50961

To access the conference call, dial 888-999-3182 within the U.S. or 848-280-6330 outside the U.S. Passcode: XTANT Medical Holdings.

A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ‘‘expects,'' ‘‘anticipates,'' ‘‘plans,'' ‘‘believes,'' ‘‘estimates,'' "continue," "future," ‘‘will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's financial guidance for 2024 and expectations for additional new product launches, further margin improvement on higher sales and the generation of positive operating cash flow. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; risk associated with its recently announced private placement; anticipated shortages of stem cells which will adversely affect future revenues; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 anticipated to be filed with the SEC. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact:

Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except number of shares and par value)


June 30, 2024

December 31, 2023




ASSETS



Current Assets:



Cash and cash equivalents

$

5,379

$

5,715

Restricted Cash

99

208

Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $1,012 and $920, respectively

21,187

20,731

Inventories

40,507

36,885

Prepaid and other current assets

1,800

1,330

Total current assets

68,972

64,869


Property and equipment, net

8,837

8,692

Right-of -use asset, net

1,117

1,523

Goodwill

7,302

7,302

Intangible assets, net

9,220

10,085

Other assets

130

141

Total Assets

$

95,578

$

92,612


LIABILITIES & STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable

$

6,875

$

7,054

Accrued liabilities

8,676

10,419

Current portion of lease liability

794

830

Current portion of finance lease obligations

67

65

Line of credit

11,899

4,622

Total current liabilities

28,311

22,990

Long-term Liabilities:

Lease liability, less current portion

376

759

Finance lease obligations, less current portion

82

116

Long-term debt, plus premium and less issuance costs

21,770

17,167

Other liabilities

34

231

Total Liabilities

50,573

41,263


Stockholders' Equity

Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding

-

-

Common stock, $0.000001 par value; 300,000,000 shares authorized; 130,314,372 shares issued and outstanding as of June 30, 2024 and 130,180,031 shares issued and outstanding as of December 31, 2023

-

-

Additional paid-in capital

296,451

294,330

Accumulated other comprehensive (loss) income

(175

)

29

Accumulated deficit

(251,271

)

(243,010

)

Total Stockholders' Equity

45,005

51,349


Total Liabilities & Stockholders' Equity

$

95,578

$

92,612

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)


Three Months Ended
June 30,

Six Months Ended
June 30,


2024

2023

2024

2023






Revenue

$

29,943

$

20,232

$

57,816

$

38,176

Cost of sales

11,361

7,773

21,932

15,180

Gross Profit

18,582

12,459

35,884

22,996


Gross Profit %

62.1

%

61.6

%

62.1

%

60.2

%


Operating Expenses

General and administrative

7,713

4,954

15,498

9,839

Sales and marketing

13,179

8,716

25,639

15,770

Research and development

636

180

1,163

354

Total Operating Expenses

21,528

13,850

42,300

25,963


Loss from Operations

(2,946

)

(1,391

)

(6,416

)

(2,967

)


Other Expense

Interest expense

(992

)

(786

)

(1,827

)

(1,360

)

Interest income

-

-

-

85

Unrealized foreign currency translation loss

118

-

79

-

Other income

(5

)

-

7

-

Total Other Expense

(879

)

(786

)

(1,741

)

(1,275

)

Net Loss from Operations Before Provision for Income Taxes

(3,825

)

(2,177

)

(8,157

)

(4,242

)


Provision for Income Taxes

Current and Deferred

(36

)

(13

)

(104

)

(26

)

Net Loss

$

(3,861

)

$

(2,190

)

$

(8,261

)

$

(4,268

)


Net Loss Per Share:

Basic

$

(0.03

)

$

(0.02

)

$

(0.06

)

$

(0.04

)

Dilutive

$

(0.03

)

$

(0.02

)

$

(0.06

)

$

(0.04

)


Shares used in the computation:

Basic

130,269,710

108,897,048

130,291,796

108,895,327

Dilutive

130,269,710

108,897,048

130,291,796

108,895,327

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)


Six Months Ended
June 30,


2024

2023

Operating activities:



Net loss

$

(8,261

)

$

(4,268

)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

2,003

1,274

Gain on disposal of fixed assets

(142

)

(21

)

Non-cash interest

218

189

Stock-based compensation

2,138

1,056

Provision for reserve on accounts receivable

178

225

Provision for excess and obsolete inventory

388

243

Other

1

3


Changes in operating assets and liabilities, net of the effects of the acquisition:

Accounts receivable

(688

)

(3,116

)

Inventories

(4,130

)

(1,733

)

Prepaid and other assets

(469

)

(330

)

Accounts payable

(15

)

954

Accrued liabilities

(2,064

)

758

Net cash used in by operating activities

(10,843

)

(4,766

)

Investing activities:

Purchases of property and equipment

(1,337

)

(870

)

Proceeds from sale of fixed assets

183

55

Acquisition of Surgalign SPV, Inc.

-

(17,000

)

Net cash used in investing activities

(1,154

)

(17,815

)

Financing activities:

Payments on financing leases

(32

)

(30

)

Borrowings on line of credit

59,565

36,256

Repayments of line of credit

(52,288

)

(34,603

)

Proceeds from issuance of long term debt

5,000

5,000

Debt issuance costs

(615

)

(101

)

Payment of taxes from withholding of common stock on vesting of restricted stock units

(17

)

-

Net cash provided by financing activities

11,613

6,522


Effect of exchange rate changes on cash and cash equivalents and restricted cash

(61

)

-


Net change in cash and cash equivalents and restricted cash

(445

)

(16,059

)

Cash and cash equivalents and restricted cash at beginning of period

5,923

20,507

Cash and cash equivalents and restricted cash at end of period

$

5,478

$

4,448



Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets

Cash and cash equivalents

$

5,379

$

4,138

Restricted cash

99

310

Total cash and restricted cash reported in the condensed consolidated balance sheets

$

5,478

$

4,448

XTANT MEDICAL HOLDINGS, INC.
Calculation of Non-GAAP Consolidated EBITDA and Adjusted EBITDA
(Unaudited, in thousands)


Three Months Ended
June 30,

Six Months Ended
June 30,


2024

2023

2024

2023






Net Loss

$

(3,861

)

$

(2,190

)

$

(8,261

)

$

(4,268

)


Depreciation and amortization

998

803

2,003

1,274

Interest expense

992

786

1,827

1,275

Tax expense

36

13

104

26

Non-GAAP EBITDA

(1,835

)

(588

)

(4,327

)

(1,693

)


Non-GAAP EBITDA/Total revenue

-6.1

%

-10.7

%

-7.5

%

-4.4

%


NON-GAAP ADJUSTED EBITDA CALCULATION

Non-cash compensation

1,228

439

2,138

1,056

Acquisition-related expenses

-

254

338

465

Acquisition-related fair value adjustments

1,229

-

2,530

-

Foreign currency exchange gain

(118

)

-

(79

)

-

Non-GAAP Adjusted EBITDA

$

504

$

105

$

600

$

(172

)

SOURCE: Xtant Medical Holdings, Inc.



View the original press release on accesswire.com

FAQ

What was Xtant Medical's (XTNT) revenue growth in Q2 2024?

Xtant Medical (XTNT) reported a revenue growth of 48% in Q2 2024, with total revenue reaching $29.9 million compared to $20.2 million in the prior year quarter.

How did Xtant Medical's (XTNT) gross margin change in Q2 2024?

Xtant Medical's (XTNT) gross margin improved by 50 basis points in Q2 2024, reaching 62.1% compared to 61.6% in the prior year quarter.

What is Xtant Medical's (XTNT) revenue guidance for full-year 2024?

Xtant Medical (XTNT) reaffirmed its full-year 2024 revenue guidance of $116 million to $120 million, representing an annual revenue growth of approximately 27% to 31% compared to 2023.

How many new distributors did Xtant Medical (XTNT) sign in Q2 2024?

Xtant Medical (XTNT) signed 15 new distributors in the second quarter of 2024.

What was Xtant Medical's (XTNT) Adjusted EBITDA for Q2 2024?

Xtant Medical (XTNT) reported a positive Adjusted EBITDA of $0.5 million for Q2 2024, compared to $0.1 million in the prior-year period.

Xtant Medical Holdings, Inc.

NYSE:XTNT

XTNT Rankings

XTNT Latest News

XTNT Stock Data

76.50M
138.71M
8.33%
69.16%
0.13%
Medical Devices
Biological Products, (no Disgnostic Substances)
Link
United States of America
BELGRADE